112 related articles for article (PubMed ID: 37658770)
1. Src is a target molecule of mannose against pancreatic cancer cells growth in vitro & in vivo.
Xie J; Wu S; Liao W; Ning J; Ding K
Glycobiology; 2023 Oct; 33(10):766-783. PubMed ID: 37658770
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
3. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
4. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.
Brown M; Zhang W; Yan D; Kenath R; Le L; Wang H; Delitto D; Ostrov D; Robertson K; Liu C; Pham K
PLoS One; 2020; 15(1):e0226917. PubMed ID: 31929540
[TBL] [Abstract][Full Text] [Related]
5. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics analyses of infiltrating immune cell participation on pancreatic ductal adenocarcinoma progression and in vivo experiment of the therapeutic effect of Shuangshen granules.
Hu J; Jiang J; Xu B; Li Y; Wang B; He S; Ren X; Shi B; Zhang X; Zheng H; Hua B; Liu R
J Ethnopharmacol; 2024 Mar; 322():117590. PubMed ID: 38113986
[TBL] [Abstract][Full Text] [Related]
7. Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux.
Carozzo A; Yaneff A; Gómez N; Di Siervi N; Sahores A; Diez F; Attorresi AI; Rodríguez-González Á; Monczor F; Fernández N; Abba M; Shayo C; Davio C
Mol Pharmacol; 2019 Jul; 96(1):13-25. PubMed ID: 31043460
[TBL] [Abstract][Full Text] [Related]
8. ABCC3 is a novel target for the treatment of pancreatic cancer.
Adamska A; Ferro R; Lattanzio R; Capone E; Domenichini A; Damiani V; Chiorino G; Akkaya BG; Linton KJ; De Laurenzi V; Sala G; Falasca M
Adv Biol Regul; 2019 Aug; 73():100634. PubMed ID: 31053501
[TBL] [Abstract][Full Text] [Related]
9. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
10. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
11. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
[TBL] [Abstract][Full Text] [Related]
12. lncRNA
Li N; Yang G; Luo L; Ling L; Wang X; Shi L; Lan J; Jia X; Zhang Q; Long Z; Liu J; Hu W; He Z; Liu H; Liu W; Zheng G
Clin Cancer Res; 2020 Apr; 26(7):1736-1748. PubMed ID: 31831555
[TBL] [Abstract][Full Text] [Related]
13. SQLE inhibition suppresses the development of pancreatic ductal adenocarcinoma and enhances its sensitivity to chemotherapeutic agents in vitro.
Zhao F; Huang Y; Zhang Y; Li X; Chen K; Long Y; Li F; Ma X
Mol Biol Rep; 2022 Jul; 49(7):6613-6621. PubMed ID: 35552960
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma.
Zhang C; Atri P; Nallasamy P; Parte S; Rauth S; Nimmakayala RK; Marimuthu S; Chirravuri-Venkata R; Bhatia R; Halder S; Shah A; Cox JL; Smith L; Kumar S; Foster JM; Kukreja RC; Seshacharyulu P; Ponnusamy MP; Batra SK
Cancer Lett; 2022 Dec; 551():215922. PubMed ID: 36285687
[TBL] [Abstract][Full Text] [Related]
15. Functional roles of SRC signaling in pancreatic cancer: Recent insights provide novel therapeutic opportunities.
Poh AR; Ernst M
Oncogene; 2023 Jun; 42(22):1786-1801. PubMed ID: 37120696
[TBL] [Abstract][Full Text] [Related]
16. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma.
Song X; Chen H; Zhang C; Yu Y; Chen Z; Liang H; Van Buren G; McElhany AL; Fisher WE; Lonard DM; O'Malley BW; Wang J
Cancer Lett; 2019 Feb; 442():310-319. PubMed ID: 30423406
[TBL] [Abstract][Full Text] [Related]
17. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
18. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
19. PRMT1 promotes pancreatic cancer growth and predicts poor prognosis.
Song C; Chen T; He L; Ma N; Li JA; Rong YF; Fang Y; Liu M; Xie D; Lou W
Cell Oncol (Dordr); 2020 Feb; 43(1):51-62. PubMed ID: 31520395
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
